Dermata Therapeutics Reports Positive Phase 3 Trial Results

An announcement from Dermata Therapeutics ( (DRMA) ) is now available.

Dermata Therapeutics announced positive results from its Phase 3 STAR-1 clinical trial for XYNGARI™ in treating moderate-to-severe acne, achieving statistically significant results at weeks 4 and 12. The company raised $8.8 million in the first half of 2025, which is expected to fund operations into the second quarter of 2026, and is preparing for the second Phase 3 trial, STAR-2, which will be followed by a 9-month extension study.

The most recent analyst rating on (DRMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.

Spark’s Take on DRMA Stock

According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.

Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.

To see Spark’s full report on DRMA stock, click here.

More about Dermata Therapeutics

Dermata Therapeutics is a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications. The company’s lead product candidate, XYNGARI™, is derived from a naturally sourced freshwater sponge and has been studied for the treatment of acne, psoriasis, and rosacea. Dermata is headquartered in San Diego, California.

Average Trading Volume: 15,463

Technical Sentiment Signal: Sell

Current Market Cap: $3.9M

Find detailed analytics on DRMA stock on TipRanks’ Stock Analysis page.